BOSTON ( TheStreet) -- Investing in biotech stocks is tricky. Biotechs are usually unprofitable and burn through cash, appearing destined for shareholder dilution or bankruptcy court. Yet, those that do succeed deliver obscene returns. Dendreon (DNDN), which developed the Provenge prostate-cancer drug, has surged, on average, 68% a year since 2007.Here are 10 of the highest-rated biotech stocks. They're exceptionally risky, but predicted by analysts to double, triple, quadruple or even quintuple in the next 12 months. Below, they are ordered by projected return, from big to biggest. Investors should investigate each company and its drug candidates.
10 Biotech Stocks Expected to at Least Double
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.